Cell Culture Contamination Part 1 – Understanding Cell Culture Contamination
Recent studies have shown that at least 20% of the animal cell cultures currently in use in the US are contaminated by either microorganisms or other cell lines. This three part live, on-line seminar series will review the scope of this major problem and examine some of its causes and techniques for avoiding it. It will also explore some key, easy to employ strategies for preventing these losses by careful culture management.
This webinar will discuss good aseptic technique: developing a practical approach to aseptic technique; reducing day-to-day contamination problems in the lab; and helpful hints for avoiding contamination.
RecordedJun 11 201346 mins
Your place is confirmed, we'll send you email reminders
Organogenesis to Oncogenesis: Modeling Development and Cancer with Organoids
Organoid cell culture allows mammalian stem cells to differentiate and self-organize into three-dimensional organ-like tissues that reflect the key structural and functional properties of the organs from which they are derived. In addition, organoids can be grown from patient-derived healthy and tumor tissue to provide genetically and phenotypically stable personalized preclinical models. Organoid technologies therefore provide a unique in vitro system in which to study human organ development and cancer.
In this webinar, Dr. Regan will discuss the use of organoid technologies to study organogenesis and cell fate determination in the postnatal mammary gland. In addition, the use of patient-derived organoids (PDOs) to elucidate the molecular mechanisms that regulate oncogenesis and contribute to tumor heterogeneity in colon cancer will be discussed.
Dr. Joseph Regan graduated from The Institute of Cancer Research (University of London, UK) with a Ph.D. in Cell Biology and received postdoctoral training at the Breast Cancer Now Research Centre (London, UK) and the Max Planck Institute for Molecular Genetics (Berlin, Germany). Dr. Regan subsequently worked as a Research Scientist with Bayer AG and the Charité Medical University (Berlin, Germany), where he uses patient-derived organoid models to study cancer stem cells and tumor heterogeneity in colon cancer.
This webinar will discuss advanced 3D cell culture applications that will include organoids, immune oncology, and screening in 3D cell culture. Additionally, it will review tips and tricks for optimizing 3D cell culture assays covering topics such as scaffold and scaffold free solutions, automation and various assay outputs.
Vaccines are considered to be one of the biggest public health achievements of the past century, and the concept of stimulating the organism’s immune response is the basis underlying vaccination. Vaccines act by initiating the innate immune response when activating antigen presenting cells, inducing a protective response towards a pathogen. These agents may contain live-attenuated, inactivated, or only parts of a pathogen. In this context, Corning provides a diverse set of single-use products for upstream vaccine manufacturing needs. As scale-up progresses, vessels and surfaces constantly increase in space efficacy, reducing the cost and minimizing the labor per titer. This presentation aims to provide background information about the main forms of vaccine designs, R&D and manufacturing workflows, and updated data generated in Corning’s application labs.
Presenter Bio: After graduating from Biochemistry in the University of Santiago (Chile), Constanza pursued directly a career in the Chilean Vaccine R&D industry, developing as a bioprocess scientist for both bacterial and viral vaccines in the field of animal health, being in charge of scale-up, and tech transfer with manufacturing plants. She furthered developed her career in Belgium as a bioprocess scientist, this time in the field of recombinant protein production, pursuing protocol optimization and scale-up experiments with suspension mammalian cell lines. Constanza is currently a field applications scientist in Corning for the EMEA region, providing customers with in-depth technical support, presenting seminars and trainings, and assisting customers in experimental set-up and troubleshooting.
We are happy to welcome Dr. Asunción Fernández-Barral, Instituto de Investigaciones Biomedicas "Alberto Sols", CIBERONC, Madrid, Spain as a guest presenter where she will discuss her research into the regulatory role of vitamin D in relation to human colon stem cells and its implications in colorectal cancer.
Hans Clevers’ group changed the rules of the game when they isolated and grew in vitro adult stem cells from normal and tumor intestinal tissue. These cells, embedded in an extracellular matrix that allows their growth in 3D, better reflect the genetic background, cellular heterogeneity, structure, and functionality of their tissue of origin. These structures derived from stem cells were called organoids and can be obtained from multiple organs of different species. Organoids constitute an alternative for animal models and 2D culture and are a promising tool for basic research, disease modelling, drug development, personalized treatments, and regenerative medicine.
The Instituto de Investigaciones Biomedicas "Alberto Sols", CSIC-UAM has used 3D cell culture technology to create a unique living biobank of organoids from healthy and tumor colon tissue of over 90 colorectal cancer patients. Using this valuable material, we have studied the role of vitamin D in colon homeostasis and its protective action against colon cancer. Additionally, we have also developed a reproducible drug screening system in tumor colon organoids.
Asunción Fernández-Barral obtained her Biology and Biochemistry degrees at University of Navarra (Pamplona, Spain). She received her Ph.D based on studying the antitumoral effects of pigment epithelium-derived factor (PEDF) in melanoma at the “Alberto Sols” Biomedical Research Institute (IIB; Madrid, Spain).
Asunción has become an expert in 3D-Organoid Technology by isolating and culturing patient-derived organoids (PDO) from healthy and tumour surgical and endoscopic biopsies of colorectal patients.
Shuang Zhang, PhD Postdoctoral Fellow NYU School of Medicine, Sonia Iyer, PhD, Jens Eberhardt CEO & Co-founder Automated Lab
Scientists strive for recapitulation. A seemingly odd goal to reach for at first glance, yet, during experimentation, a fundamental objective is to introduce as few variables as possible while simultaneously trying to recreate in vivo conditions as closely as possible. For decades, two-dimensional cell culture was not only the best way to study the cell biology of healthy and diseased tissue—in many cases, it was the only way. But now, we are in the 21st century, and technological innovations in biomedical sciences have allowed investigators to get closer than ever to an accurate recapitulation of tissue and organ systems. Advanced 3D cell culture methods, such as the development of spheroids and organoids, have become increasingly popular and are revolutionizing approaches to drug discovery, cancer research, and other disease modeling applications. These more in vivo like models show great promise in furthering research in critical areas by delivering more physiologically relevant results.
In this on-demand GEN webinar, the presenters explore two 3D cell culture paths: one using complex organoid models and CRISPR/Cas9 technology to understand the tumor microenvironment, including gene expression signatures and responses to immunotherapies. The other using novel microcavity spheroid technology to generate thousands of viable and productive monoclonal cell lines for several applications.
Audrey Bergeron, Applications Scientist & Ann E. Rossi, Ph.D, Senior Bioprocess Applications Scientist, Corning Life Sciences
Advanced cell culture techniques and scale-up offer exciting research opportunities; however, they also come with complex challenges and questions. Corning Life Sciences knows cells – you might even say it’s in our DNA with over 100 years of experience in the field.
In this webinar, Corning scientists put their expertise in the areas of 3D cell culture and bioprocess to work as they answered submitted questions from the audience.
•Our lab is new to working with spheroids. What are some options for spheroid formation? (2:02 - 4:10)
•How do you perform media changes in the 96-well Corning spheroid microplate without losing spheroids? (4:11 - 5:49)
•How do you dissociate single cells from a spheroid for analysis? (5:50 - 6:51)
•How do you transfer spheroids? (6:54 - 7:30)
•What is the surface area of the Corning® CellSTACK® 10-layer vessels? (7:56 - 10:02)
•Is there an easier way to fill Corning CellSTACK 10-layer vessels? (10:03 - 11:33)
•What is the maximum culture volume for the 5L expansion bag? (11:34 - 13:25)
•What cell types can I culture in the 5L Erlenmeyer flask? (13:26 - 15:25)
Live Q&A session with audience (16:10 - 29:30)
•How do you prevent organoids from sticking to collection tubes?
•How do I check the cell confluence in a HYPERFlask?
•And many more questions
Three-dimensional Models: Organoid Study and Co-culture for Oncology
Three-dimensional (3D) cell culture environments provide structural and biochemical clues for cellular differentiation and functionality. For specialized cell types such as primary cells and stem cells, a two-dimensional (2D) growth substrate may not be sufficient to support complex cellular behaviors such as cell polarity, morphology, spheroid formation, signal transduction, and tissue-specific gene expression. This seminar will introduce the newest tools developed to help researchers: Corning® Matrigel® matrix for organoid culture and Corning Elplasia® plates for bulk production of spheroids. We will also present advanced case studies using spheroids and organoids.
Franziska Wienholz is a Scientific Support Specialist at Corning Life Sciences.
Retinal Organoids: Developing Disease Models to Better Understand Glaucoma Pathogenesis
Glaucoma refers to a group of complex genetic diseases that affect the retinal ganglion cells that relay visual input along the optic nerve to the visual cortex. In glaucoma, these cells are damaged and degenerate, resulting in permanent progressive visual field loss and ultimately, blindness. Retinal organoids are routinely used to model glaucoma in vitro; however, a drawback is the lengthy culture times to generate retinal ganglion cells, which can be 2 months or longer. This can be reduced by using a 3D Corning Matrigel matrix culture, which has been used to generate retinal ganglion cells in just 28 days. With advances in gene editing, retinal organoids can be used to model genetic mutations that lead to the development of glaucoma and provide clues to future therapies to halt the loss of vision.
Philip Wagstaff is currently a Ph.D. researcher studying the genetics of glaucoma at University of Amsterdam, Netherlands.
3D culture experts from Corning and Promega answer questions about common methods to form 3D structures, and factors to consider when evaluating cell-based assays for use with 3D structures. Learn about the novel viability and cytotoxicity assays that do not lyse cells and allow for additional multiplexing with nucleic acid purification or other markers of cell function.
Dr. Terry Riss started the Cell Biology program at Promega Corporation in 1990 and held several R&D and Project Management positions since. Dr. Riss managed development of cell viability, cytotoxicity, apoptosis, and protease assay systems and also lead efforts to identify and promote multiplexing of cell-based assays to determine the mechanism of cell death. Dr. Riss now serves as Senior Product Manager, Cell Health involved in outreach educational training activities including validating assay systems applied to 3D cell culture models. Dr. Riss also serves as an editor of the In Vitro Cell-Based Assays section of the Assay Guidance Manual hosted by The National Center for Advancing Translational Sciences (NCATS) at the NIH.
Dr. Austin Mogen is a Field Application Scientist at Corning Life Sciences. He received his doctorate from the University of Florida and gained industry experience as both a Senior Scientist of upstream process development and Supervisor for manufacturing of viral vectors. In this position he focused on bioprocess development, closed system solutions for cell culture scale-up, and production of viral vectors for cell and gene therapy. Dr. Mogen works extensively with academic researchers and process development groups, optimizing cell culture assays and cellular scale-up conditions. In addition, he focuses on collaborations utilizing high-end 3D technology products such as the Corning spheroid microplates, transwell inserts, and extracellular matrices to provide more in vivo models for biological research and therapeutic response.
The prognosis of patients with glioblastoma (GBM) remains dismal with a median survival of approximately 15 months. Current preclinical GBM models are limited by the lack of a “normal” human microenvironment and the inability of many tumor cell lines to accurately reproduce GBM biology. To address these limitations, our guest presenter and her team have established a unique model system whereby they can retro-engineer patient-specific GBMs using patient-derived glioma stem cells (GSCs) and human embryonic stem cell (hESC)-derived cerebral organoids. Their cerebral organoid glioma (GLICO) model shows that GSCs home toward the human cerebral organoid, and deeply invade and proliferate within the host tissue forming tumors that closely phenocopy patient GBMs. Furthermore, cerebral organoid tumors form rapidly and are supported by an interconnected network of tumor microtubes that aids in the invasion of normal host tissue. This GLICO model provides a new system for modeling primary human GBM ex vivo and for high throughput drug screening.
Guest Presenter Bio:
Dr. Amanda Linkous previously served as the Director of the Starr Foundation Cerebral Organoid Translational Core at Weill Cornell Medicine (New York, NY). She completed her postdoctoral training in the Neuro-Oncology Branch at the National Cancer Institute (Bethesda, MD). Dr. Linkous is currently the Scientific Center Manager for the NCI's Center for Systems Biology of Small Cell Lung Cancer (SCLC) at Vanderbilt University, where she is developing similar 3D model systems to study the biology and refractory nature of SCLC (Nashville, TN)
Cell culture is a fundamental technique for a variety of applications. Cells are cultured in controlled conditions including temperature, gas exchange, pH, and culture media (energy and nutrients). This webinar will introduce basic concepts of cell culture and provide tips on how to succeed in culturing mammalian cells.
In this webinar, we will review:
•Introduction to cell culture
•Critical factors for successful cell culture
•Cell culture tips and techniques
Dr. Kyung-A Song graduated from Sungkyunkwan University with a Ph.D. in molecular biology and cancer immunology. She completed her postdoctoral fellowship in pharmaceutical research and drug discovery at Virginia Commonwealth University. She has extensive experience in a variety of cell culture techniques including isolation and culture of primary patient cells. She has worked with xenograft models and many cancer cell lines, and she has expertise in in vitro cell based functional assays and in vivo experiments. She is currently a Scientific Support Specialist for Corning Life Sciences where she answers customer inquiries about all products in the extensive Corning Life Sciences product portfolio.
In recent years, three-dimensional (3D) cell culture models have been emerging as the preferred in vitro cancer model as they better mimic the in vivo tumor microenvironment. For instance, 3D cultures develop hypoxic cores and demonstrate gradients of soluble factors and a diffusion profile for drugs similar to solid tumors. Understanding the interactions between cancer cells and other cell types in the tumor microenvironment is also critical to predicting therapeutic efficacy.
In this webinar, Audrey Bergeron will review:
•An introduction to 3D cell culture
•Assay techniques in spheroid microplates
•Several 3D cancer models and technology tools used to better capture the complexity of the tumor microenvironment in assay-compatible formats.
About the Presenter:
Audrey Bergeron is an applications scientist for Corning Life Sciences. She evaluates new products and develops protocols and technical documents using Corning cell culture products. She also provides product training to Corning employees and customers, and assists technical services with customer support by helping to troubleshoot customer experiments.
Franziska Wienholz, Scientific Support Specialist, Corning Life Sciences
Cell Culture Masterclass: A 10-Point Plan to Prevent Contamination
All cell culture laboratories have experienced it: cell culture contamination and its inevitable loss of material. Contaminants may be biological or chemical, visible or invisible, destructive or seemingly benign, but in all cases, they adversely affect both the use of your cell cultures and the quality of your research.
Identification and, even better, prevention of contamination are crucial for ensuring high-quality research. This expert webinar will present an overview on how to prevent, recognize and tackle contamination by introducing good lab practices and targeted interventions.
If you work with cell culture daily or are interested in setting up prevention strategies to minimize contamination, then join SelectScience and Franziska Wienholz, scientific support specialist of Corning Life Sciences, for this educational masterclass. Franziska will share a 10-point plan to prevent contamination and provide a comprehensive refresher on all aspects of cell culture.
Key learning objectives:
Understand the basic rules of cell culture
Know how to properly manage cell lines to prevent cross-contamination
Be able to implement a 10-point plan to contamination prevention in your laboratory
Who should attend:
Scientists working with cell culture on a daily basis
Cell culture managers who are interested in setting up programs to prevent contamination and determine authentication of cells
Researchers that struggle with contamination issues
Dr. Richard E. Eglen, Vice President and General Manager, Corning Life Sciences.
Advances in three-dimensional Cell Culture in Drug Research, Discovery and Biologic Manufacture.
Cellular research is optimal when using physiologically relevant cell phenotypes and genotypes of human origin. This assertion has accelerated the adoption of primary cells, stem cells, and, increasingly, patient-specific cells in drug discovery. Over the past five years, technological improvements in 3D cell culture technology, to better mimic in vivo physiology, have also advanced. This is true not only in the areas of cancer and neurological research, but also in the assessment of clinical candidates for metabolic and toxicological liabilities. Furthermore, 3D cell culture is facilitating novel approaches to both the scale-up and manufacture of biologics, including those used in immuno- and stem cell-based therapies.
Are you a scientist interested in 3D cell culture? Join this expert webinar, in which Dr. Richard Eglen will discuss the importance of 3D cell culture in drug discovery and manufacture and how technological improvements are causing significant advancements in this field.
- The existing and future impacts of 3D cell culture technology on fundamental research
- The impacts of 3D cell culture on drug discovery and manufacture, particularly in the context of using phenotypically relevant cells?
- The potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development?
The Corning Scientific Seminar Series is a series of free, online technical presentations that provide novel tips, best practices and proven techniques to help advance your research. Delivered by scientists to scientists, these one-hour broadcasts offer useful information and tips for lab technicians and researchers.